Genomic and multi-omic insights into the heterogeneity of diabetic kidney disease.
文献摘要
Diabetic kidney disease (DKD) is a leading cause of kidney failure and excess morbidity and mortality. Once regarded as a uniform microvascular complication of chronic hyperglycaemia, DKD is now recognized as a biologically and clinically heterogeneous condition. Not all chronic kidney disease in individuals with diabetes can be attributed to diabetes, and distinguishing DKD from non-diabetic kidney disease (non-DKD) is essential for appropriate management. Multiple interacting pathways, including hyperglycaemia, haemodynamic stress, dyslipidaemia, obesity, inflammation and ancestry-specific genetic risk, drive diverse patterns of kidney injury and clinical trajectories. Conventional classification based on glomerular filtration rate or albuminuria alone fails to capture this complexity. Emerging multi-omics approaches are reshaping our understanding of DKD by identifying genomic, epigenomic, proteomic and metabolomic signatures that stratify risk, elucidate mechanisms and inform therapeutic response. Integration of these molecular layers with polygenic scores, data-driven clustering and single-cell kidney atlases is beginning to define disease endotypes and guide precision-medicine strategies. Large-scale collaborative efforts that combine deep phenotyping, biobanking and advanced analytics are accelerating the translation of molecular heterogeneity into actionable biomarkers and therapeutic targets. Despite ongoing challenges - including the need for validation, equitable representation and clinical implementation - omics-driven precision approaches offer the potential to transform DKD management by reducing residual risk and enabling more effective, precision interventions.